Chester County News and Community Website
NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) expects its existing cash and anticipated at-the-market equity proceeds to fund operations only into the first quarter of 2027, leaving the clinical-stage …
Traws Faces 2027 Funding Gap as Flu Drug Remains on Hold Read More NEWTOWN, PA — Traws Pharma (NASDAQ: TRAW) said this week it is preparing additional toxicology data requested by U.K. regulators, delaying the planned launch of a Phase 2a human influenza …
Traws Pharma Delays Influenza Study as UK Regulator Seeks More Data Read More NEWTOWN, PA — Traws Pharma Inc. (NASDAQ: TRAW) has deferred a planned Phase 2a human influenza challenge study of its lead antiviral candidate tivoxavir marboxil after receiving unfavorable feedback from …
Traws Delays Influenza Study After UK Regulatory Setback Read More NEWTOWN, PA — Traws Pharma (Nasdaq: TRAW) is advancing development of a broad-spectrum antiviral combination designed to target multiple high-risk viral diseases, including hantavirus, Ebola, and Lassa fever, as the …
Traws Advances Broad-Spectrum Antiviral as Outbreak Risks Grow Read More NEWTOWN, PA — Traws Pharma, Inc. (Nasdaq: TRAW) secured up to $60 million in new financing and outlined plans to begin a human influenza challenge trial for its lead antiviral …
Traws Extends Runway With Financing as Flu Trial Nears Read More NEWTOWN, PA — Traws Pharma (Nasdaq: TRAW) plans to advance antiviral drug candidates targeting hantavirus infections as the company seeks to expand its respiratory virus pipeline amid renewed concerns over …
Traws Pharma Targets Hantavirus Amid Rising Outbreak Concerns Read More NEWTOWN, PA — Traws Pharma, Inc. (Nasdaq: TRAW) reported its financial results for the year ended December 31, 2025, and outlined progress across its antiviral pipeline, alongside a private financing …
Traws Pharma Reports 2025 Results, Secures Up to $60M Financing Read More NEWTOWN, PA — Traws Pharma, Inc. (Nasdaq: TRAW) announced completion of a 90-patient Phase 2 study evaluating its investigational COVID-19 treatment ratutrelvir against PAXLOVID® and provided an update on development …
Traws Pharma Reports Phase 2 COVID-19 Data, Flu Program Update Read More NEWTOWN, PA — Traws Pharma, Inc. (Nasdaq: TRAW) said it has completed enrollment in a 90-patient Phase 2 study testing its experimental oral COVID-19 treatment ratutrelvir against PAXLOVID®, reporting early …
Experimental COVID Pill Shows Edge Over Paxlovid as Traws Hits Key Milestones Read More NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) said it has taken a key step toward federal preparedness planning by filing an investigational new drug application for its influenza candidate …
Traws Targets Stockpile Nod as COVID Drug Outperforms Paxlovid in Trial Read More